H Lundbeck A/S (HLUYY) Upgraded to Buy by Zacks Investment Research

Zacks Investment Research upgraded shares of H Lundbeck A/S (OTCMKTS:HLUYY) from a hold rating to a buy rating in a research report sent to investors on Wednesday morning. Zacks Investment Research currently has $62.00 target price on the stock.

According to Zacks, “H. Lundbeck A/S is an international pharmaceutical company engaged in the research and development, production, marketing and sale of pharmaceuticals across the world. Its products are targeted at disorders like depression and anxiety, schizophrenia, insomnia, Huntington’s, epilepsies, Alzheimer’s and Parkinson’s diseases. The Company is involved in the development of new and improved drugs for the treatment of psychiatric and neurological disorders. H. Lundbeck A/S is headquartered in Copenhagen, Denmark. “

Separately, Deutsche Bank AG lowered shares of H Lundbeck A/S from a hold rating to a sell rating in a research report on Friday, July 28th.

Shares of H Lundbeck A/S (OTCMKTS HLUYY) opened at $56.52 on Wednesday. H Lundbeck A/S has a 52-week low of $37.21 and a 52-week high of $66.67. The company has a debt-to-equity ratio of 0.08, a current ratio of 1.21 and a quick ratio of 0.93. The firm has a market cap of $11,189.90, a P/E ratio of 26.04, a price-to-earnings-growth ratio of 1.16 and a beta of 0.27.

COPYRIGHT VIOLATION NOTICE: This piece of content was published by Sports Perspectives and is the property of of Sports Perspectives. If you are accessing this piece of content on another domain, it was illegally stolen and republished in violation of United States and international copyright and trademark law. The original version of this piece of content can be accessed at https://sportsperspectives.com/2017/11/19/h-lundbeck-as-hluyy-upgraded-to-buy-by-zacks-investment-research.html.

H Lundbeck A/S Company Profile

H Lundbeck A/S is a Denmark-based company active in the pharmaceuticals industry. It is engaged in the research, development, manufacture and marketing of pharmaceuticals for the treatment of brain disorders, such as Alzheimer’s disease, Bipolar disorder, depression, epilepsy, Huntington’s disease, Parkinson’s disease and schizophrenia.

Get a free copy of the Zacks research report on H Lundbeck A/S (HLUYY)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for H Lundbeck A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for H Lundbeck A/S and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply